Skip to content
lifestyle.childcarepartnerships.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Adagene Inc.
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
October 28, 2026
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
October 27, 2026
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
October 14, 2026
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
September 22, 2026
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
September 10, 2026
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
September 9, 2026
Adagene to Participate in Three Upcoming Investor Conferences
August 20, 2026
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
August 12, 2026
Adagene to Participate in Two Upcoming Investor Conferences
May 12, 2026